12th Aug 2021 14:17
Immupharma PLC - London-based pharmaceutical company - Says US Food & Drug Administration approves pharmacokinetic study, as part of the phase 3 trial, of potential lupus treatment Lupuzor. Notes the study will assess the presence of Lupuzor in the body after a single dose is administered. Says the study will include 24 healthy male subjects and take from 8 to 12 weeks to complete. Plans to begin Phase 3 study after the completion of the pharmacokinetic study.
Chief Executive Tim McCarthy says: "We are extremely pleased to see the next positive steps for Lupuzor, with continued positive dialogue with the FDA, their approval to commence the PK study and an agreed clinical and regulatory pathway over the next period."
Current stock price: 8.40 pence, down 2.6% on Thursday
Year-to-date change: down 37%
By Scarlett Butler; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Immupharma